

KD Pharma Acquires Phytoextract and CBD Manufacturing Assets

Transaction advances KD Pharma's cannabinoid manufacturing strategy

BIOGGIO, LUGANO, SWITZERLAND, April 12, 2021 /EINPresswire.com/ -- The KD Pharma Group has acquired the manufacturing assets of a Swissbased cannabinoid manufacturer. The assets give KD Pharma access to technology for producing Active Pharmaceutical Ingredients (APIs) based on phytocannabinoids and other plant extracts. The technology further expands KD's lipid technology portfolio and can be used in combination with KD's other fractionation and separation technologies.

"KD Pharma is a leader in lipid technology focused primarily on omega-3s, but our technology suite has applications in other lipid sources like cannabinoids," said Oscar Groet,



KD Pharma Group



Phytoextract and CBD Manufacturing Assets

CEO of the KD Pharma Group. "We have committed to expanding our technology portfolio to develop APIs from cannabinoids and plant extracts," Groet continued, "and these assets give KD Pharma additional pathways to develop new products for this emerging market."

The KD Pharma Group has also licensed a novel extraction method from Herbolea Biotech S.r.l. and expects to have a complete, licensed cGMP manufacturing facility online by the end of the year.

About the KD Pharma Group

The KD Pharma Group is a contract manufacturer that develops products in the pharmaceutical and nutraceutical space. It is also one of the largest Omega-3 fatty acid producers in the world

with over 500 employees and a presence in the UK, Norway, Germany, Switzerland and the US. The KD Pharma Group employs state-of-theart technology which is protected by numerous patents. Visit www.kdpharmagroup.com to learn more.



We have committed to expanding our technology portfolio to develop APIs from cannabinoids and plant extracts"

Oscar Groet



KD Pharma Group CBD and Phytoextracts

Adam Ismail, Chief Strategy Officer KD Pharma Group +1 385-237-2787 email us here Visit us on social media: LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/538247628

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2021 IPD Group, Inc. All Right Reserved.